Actinic Keratoses Clinical Trial
Official title:
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream in the Treatment of Thin and Moderately Thick, Non-hyperkeratotic, Non-pigmented Actinic Keratosis (AK) of the Face and Scalp When Using Daylight Photodynamic Therapy (DL-PDT)
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT).
This was a randomized, double-blind, vehicle-controlled, multicenter, parallel-group study in adult participants with clinically-confirmed mild to moderate AKs on the face and the balding scalp, to be conducted at approximately 60 clinical sites in the United States. Sites were selected to ensure that diverse daylight conditions represented in the study to understand the effects of latitude, elevation, and climate. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03575780 -
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
|
Phase 1 | |
Completed |
NCT05937529 -
Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis
|
N/A | |
Completed |
NCT02520700 -
A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses
|
N/A | |
Terminated |
NCT01538901 -
Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients
|
Phase 4 | |
Completed |
NCT01354717 -
Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo
|
Phase 3 | |
Completed |
NCT00742391 -
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
|
Phase 3 | |
Completed |
NCT03285477 -
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
|
Phase 3 | |
Suspended |
NCT03963102 -
Duration of Ameluz Application in Acral Actinic Keratoses Response
|
Phase 4 | |
Not yet recruiting |
NCT05923060 -
Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses
|
Phase 2 | |
Withdrawn |
NCT06026358 -
Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
|
Phase 4 | |
Completed |
NCT02622594 -
Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times
|
Phase 4 | |
Completed |
NCT00774787 -
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
|
Phase 4 | |
Completed |
NCT00786994 -
The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
|
Phase 2 | |
Completed |
NCT00544258 -
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
|
Phase 1 | |
Completed |
NCT04024579 -
Treatment of Actinic Keratosis With 5% KOH Solution
|
||
Completed |
NCT04843553 -
Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients
|
Early Phase 1 | |
Completed |
NCT03315286 -
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
|
N/A | |
Completed |
NCT03279328 -
Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents
|
Phase 4 | |
Completed |
NCT02062853 -
Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video
|
N/A | |
Terminated |
NCT01532453 -
Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients
|
Phase 3 |